From conventional therapies to nanomaterial platforms: A review of treatments for bacterial pneumonia
Biomedical Engineering Communications · 2027 · 6 (2) · 11
DOI: 10.53388/bmec2027011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Engineering Communications, 2027. Verfasst von Wei Luo und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Bacterial pneumonia persists as a leading global cause of infectious mortality, with patient management severely undermined by the escalating burden of antimicrobial resistance. While antibiotics remain the cornerstone of anti-infective therapy, their application is limited by single-target mechanisms, systemic toxicity, disruption of host microbiota, and the rapid emergence and dissemination of resistant phenotypes. Alternative strategies, including bacteriophage therapy, antimicrobial peptides, and immunotherapy, have demonstrated promising antibacterial efficacy; however, their clinical translation remains constrained by limited antibacterial spectra, poor biological stability, high production costs, and complex host-pathogen interactions. This review systematically examines the paradigm shift from conventional therapies to engineered nanomaterial-based interventions for bacterial pneumonia. We comparatively analyze the advantages and limitations of existing therapeutic modalities and highlight how metal nanoparticles, two-dimensional nanomaterials, and polymeric nanocarriers overcome key barriers in pulmonary infection treatment. These nanoplatforms enable targeted pulmonary delivery, stimulus-responsive drug release, prolonged local retention in lung tissues, and multimodal antibacterial mechanisms, including bacterial membrane disruption, oxidative stress induction, photothermal/photodynamic ablation, and immune modulation. Finally, we summarize recent advances in synergistic multimodal nanotherapy and discuss critical challenges in clinical translation, including biocompatibility, scalable manufacturing and regulatory frameworks. Collectively, nanomaterial-based approaches provide a promising blueprint for next-generation antibacterial strategies to address drug-resistant bacterial pneumonia.
Zitieren
APA
Luo, W., Xu, Y., Hu, X., Zhang, J., & Wang, Y. (2027). From conventional therapies to nanomaterial platforms: A review of treatments for bacterial pneumonia. Biomedical Engineering Communications, 6(2), 11. https://doi.org/10.53388/bmec2027011
Vancouver
Luo W, Xu Y, Hu X, Zhang J, Wang Y. From conventional therapies to nanomaterial platforms: A review of treatments for bacterial pneumonia. Biomedical Engineering Communications. 2027;6(2):11. doi:10.53388/bmec2027011
BibTeX
@article{Luo2027,
author = {Luo, Wei and Xu, Yuan-Yuan and Hu, Xue-Feng and Zhang, Jie-Yu and Wang, Yun-Bing},
title = {From conventional therapies to nanomaterial platforms: A review of treatments for bacterial pneumonia},
journal = {Biomedical Engineering Communications},
year = {2027},
volume = {6},
number = {2},
pages = {11},
doi = {10.53388/bmec2027011}
}
EUVIMED